Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,

Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.

The pharmaceutical company expects the expansion will create thousands of jobs.

Indianapolis-based pharmaceutical giant Eli Lilly and Co. announced plans Wednesday to add four new manufacturing sites in a roughly $27 billion investment expected to create 3,000 jobs and nearly 10,000 construction positions during the buildout.

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.